Compare Eli Lilly And Co (LLY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vital Farms Inc — how do they compare? Eli Lilly And Co trades at $1,220.05 (market cap $1.08T), while Vital Farms Inc trades at $11.48 (market cap $496.50M). The key difference: Eli Lilly And Co is far larger — about 2175.2× Vital Farms Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| LLY | VITL | |
|---|---|---|
Market Cap | $1.08T | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $52.41 |
52-Week Low | $639.43 | $8.28 |
Enterprise Value | $1.13T | $583.51M |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
VITL trades at $11.48, up 1.95% on the day, but faces significant technical headwinds with a bearish moving average signal. The company reported mixed Q2 2026 results, beating revenue estimates but posting a $0.47 per share loss amid industry oversupply challenges. Recent $125 million term loan financing provides liquidity support during this transitional period.
While analyst consensus remains positive with a $13.00 price target, near-term risks include margin compression from elevated costs and competitive pricing pressures. The stock's attractive P/S ratio of 0.67 offers value potential if the company can navigate current industry headwinds and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
